Reutilization of Immunoblots after Chemiluminescent Detection
about
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisonsProtein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cellsPoly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.An overview of technical considerations for Western blotting applications to physiological research.High cell surface death receptor expression determines type I versus type II signalingCytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignanciesA phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaEnhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase ICisplatin abrogates the geldanamycin-induced heat shock responseOvercoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell linesExpression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cellsEffects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm.HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance.Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes.Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.Rad9 protects cells from topoisomerase poison-induced cell death.Adaphostin and other anticancer drugs quench the fluorescence of mitochondrial potential probes.Measurement of BH3-only protein tolerance.A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained
P2860
Q28306393-5DEB3488-0E24-4346-802F-846CDE2337ADQ33569854-96D33AD8-E19C-4798-A16A-846DE48D5A70Q33808800-5708DD38-C2BE-4CBE-83EC-66B4E86D2075Q33947014-000CE15D-6BD8-4402-9C01-2BBA8FCBFE61Q34529689-0F5287DD-BE7F-494E-8FE7-4FE18BDD2387Q35371553-4839FD3F-6EB2-4DAF-A386-866F5441A8CDQ35525553-29832FF0-39A8-4C3F-9D99-6CC615D6A8B2Q35669226-119E3D5C-5B17-4097-B8DD-7B176900B37AQ35691439-82F5CEEB-BCA8-4165-BDE9-D794444ACBF9Q35763155-4F057397-B193-4AC9-BC59-F8C990DCB1C8Q35847836-9CF41846-8175-4EFC-A63C-41870B5C784BQ36199633-278120B9-87C7-4953-B808-2E533F9EF2B3Q36711144-10BFE746-1B8F-44F2-A9B2-19BD39CF8259Q36948038-6986564A-6145-4A1A-951E-04E2AA35F359Q36952729-E7D99361-0558-466C-B21F-4FDBC0B7B26CQ37389178-402E09CA-C014-4FE3-A867-4FE1522B3200Q37708115-229610E8-28B2-4682-9454-3C7DA227CAFAQ37726508-BC9037A4-CB06-4468-BEFF-FB3DC2BB3A74Q38340918-43A5FA01-110F-4B0D-9191-8446D45A1A05Q38445385-AF99A6B2-7691-4D79-AADF-E29DF27A5C21Q39301264-5AC4A9EC-DC57-45E4-8A6F-489B18D8DD7CQ39303314-85B51E30-781E-4886-90DE-C6B62E0524D2Q39455533-6A7AAF62-8F5D-4630-9E9C-EC7FB4E34140Q39510346-332FE4A6-735E-4264-9BF2-F8A54CB91F8DQ40094198-AC6FAB5C-D326-4B3D-8E26-FE75C5E9F1A2Q41906775-CBBFB5DF-4DB6-42F3-BFDC-BB106BE9DD9EQ42072372-DDA84B4A-D4EE-4BCD-A068-D56A78E1BB44Q44129457-27D6C888-C2A9-4E96-A4C1-6870EFDEBE66Q44779418-574CDA3A-C48C-41F5-89FC-8FD58C404FCEQ46624937-4A0BB18E-5EED-4238-9085-D8004532208CQ47624759-96FA3C1E-C078-464A-9F1F-CD559EEF661BQ53043418-279362A2-E107-4F38-8FC1-E1B1B598D9D6Q53608822-98BBD8EC-8C4B-4577-8141-0B2A88032197Q58289362-4FD52611-239A-4A4C-8977-0683A61C4FE5
P2860
Reutilization of Immunoblots after Chemiluminescent Detection
description
im September 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 September 2001
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2001
@uk
name
Reutilization of Immunoblots after Chemiluminescent Detection
@en
Reutilization of Immunoblots after Chemiluminescent Detection
@nl
type
label
Reutilization of Immunoblots after Chemiluminescent Detection
@en
Reutilization of Immunoblots after Chemiluminescent Detection
@nl
prefLabel
Reutilization of Immunoblots after Chemiluminescent Detection
@en
Reutilization of Immunoblots after Chemiluminescent Detection
@nl
P356
P1476
Reutilization of immunoblots after chemiluminescent detection
@en
P2093
Scott H. Kaufmann
P304
P356
10.1006/ABIO.2001.5313
P407
P577
2001-09-01T00:00:00Z